# Alternative Dosing Regimens of Subcutaneous Azacitidine for Myelodysplastic Syndromes

> **NCT00102687** · PHASE2 · COMPLETED · sponsor: **Celgene** · enrollment: 151 (actual)

## Conditions studied

- Myelodysplastic Syndromes

## Interventions

- **DRUG:** azacitidine

## Key facts

- **NCT ID:** NCT00102687
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-01-01
- **Primary completion:** 2008-08-01
- **Final completion:** 2008-08-01
- **Target enrollment:** 151 (ACTUAL)
- **Last updated:** 2019-11-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00102687

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00102687, "Alternative Dosing Regimens of Subcutaneous Azacitidine for Myelodysplastic Syndromes". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00102687. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*